<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="33835" whole_study_id="33835" phs="001875" v="1" p="1" createDate="2019-04-09T13:42:25-05:00" completedByGPADate="2019-04-10T09:50:59-05:00" modDate="2020-09-10T22:13:00-05:00" maxParentChildStudyModDate="2020-09-10T22:13:00-05:00" handle="VenetoclaxResistance" num_participants="5"><StudyInfo accession="phs001875.v1.p1" parentAccession="phs001875.v1.p1"><BioProject id="PRJNA558091" entrez_id="558091" type="bp_admin_access"/><BioProject id="PRJNA558092" entrez_id="558092" type="bp_data_submission"/><StudyNameEntrez>Determinants of venetoclax resistance</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="ncbi_for_sequence"/><StudyType22 name="whole_targ_exome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="tumor_normal"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>individual_sequencing</StudyType><StudyType>tumor_normal</StudyType><StudyType>whole_exome</StudyType><StudyType>sra</StudyType></StudyTypes><SraStorages><SraStorage location="NCBI"/></SraStorages></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="false" is_admin_ic="true" primary="true"/></ICs><Persons><Person nedid="CWU001" aid="2" auth="eRA" login="CWU001" fname="Catherine" mname="JU-YING" lname="Wu" email="cwu@partners.org"><Role allow_direct_access="true">PI</Role><Organization>DANA-FARBER CANCER INST</Organization></Person><Person aid="8" auth="virtual" fname="Candace" lname="Patterson" email="candace@broadinstitute.org"><Role>PI_ASSIST</Role><Organization/></Person><Person nedid="2002777465" aid="1" auth="cit" login="wuz8" fname="Zhuoxi" mname="" lname="Wu" email="joe.wu@nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0014190168" aid="1" auth="cit" login="sharopon" fname="Nataliya" mname="Rashidovna" lname="Sharopova" email="sharopon@ncbi.nlm.nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0014392987" aid="1" auth="cit" login="fingerma" fname="Ian" mname="Michael" lname="Fingerman" email="fingerma@mail.nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>We are grateful to Drs. Ta-Ming Liu, Jing Deng and Levi Garraway for constructive and valuable discussion. We are appreciative of Dr. Guo Wei (Broad Institute) for providing the MCL-1 inhibitor S63845. We acknowledge Carrie Cibulskis, Adam Tracy and Alicia Wong for expert project management. We are grateful to Amy Goodale for her skilled execution of the ORF screen, and to Ben Ferland for the immunohistochemical staining studies.

The authors would like to acknowledge support from NCI-PO1CA206978, and particularly, generous support of the Gerstner Family Foundation for the genetic screens.

R.G. was generously supported by the Fishman Family Fund. V.M.L. received support from the American Society of Hematology HONORS Award, the Harvard Medical School Scholars in Medicine Office, and the HST Research Assistant Award. A.A.J. is supported by a fellowship from the Swiss National Science Foundation. M.H-S. is supported by a grant from FEHH/Janssen (&#8216;Sociedad Espa&#241;ola de Hematolog&#237;a y Hemoterapia&#8217;). J-M.H. is supported by a Sara Elizabeth O&#8217;Brien Trust Postdoctoral Fellowship. D.B.K. is supported by NIH/NCIR21 CA216772-01A1 (to D.B.K.). J.R.B. acknowledges support from NCI (R01CA213442; 2P01CA081534) and from Susan and Gary Rosenbach Fund for Lymphoma Research. J.W.H. was supported by R37 NS083524 and R01 GM095567. V.K.M. is an investigator of the Howard Hughes Medical Institute. C.J.W. is a Scholar of the Leukemia and Lymphoma Society (LLS) and acknowledges support from NCI (1RO1CA155010-01A1; 1U10CA180861-01).</acknowledgement_statement><ic_specific_access_term/><DUC universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC><DUC_PDF universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="unrest_access" gsr_mode_label="Unrestricted access"/><ConsentGroup uid="3463" CGType="cg_class_GRU" title="General Research Use" name="GRU" dac_uid="59" dac_name="NCI DAC" irb-approval-required="No"><Use-Restriction>Use of the data is limited only by the terms of the model Data Use Certification.

</Use-Restriction></ConsentGroup><ConsentGroupLinks><ConsentGroupLink cg_uid_from="3463"><StudyTo study_uid="10253" name="dbGaP Collection: Compilation of Individual-Level Genomic Data for General Research Use" accession="phs000688.v1"><ConsentGroupTo uid="1115" name="GRU"/></StudyTo></ConsentGroupLink></ConsentGroupLinks></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study></dbgapss>